Answers are grounded in this paper and cite their sources.
Single-cell RNA sequencing (scRNA-seq) has revolutionized the study of the leukemia immune microenvironment, revealing its complex cellular composition and dynamic evolution with high resolution. This review synthesizes recent scRNA-seq-driven discoveries regarding infiltrating immune cells in leukemia, focusing on their phenotypic plasticity, functional heterogeneity, and lineage dynamics. Key findings highlight a profoundly remodeled and immunosuppressive niche. CD8 + T cells exhibit hallmarks of exhaustion, including impaired proliferation and reduced T cell receptor diversity, with clonal dynamics that trace immune editing. These cells show greater transcriptional and functional heterogeneity than CD4 + T cells, encompassing stem-like subsets vital for sustained anti-leukemic responses. Similarly, B cells, integral components of the leukemia bone marrow microenvironment, undergo stage-specific alterations during disease progression and contribute to immune evasion through their immunosuppressive functions and antigen-presenting capabilities. Concurrently, natural killer cells regulate immunity through balanced activating and inhibitory signals, while myeloid cells like tumor-associated macrophages demonstrate remarkable plasticity, collectively reinforcing an immunosuppressive network. The insights gained from scRNA-seq not only elucidate mechanisms of immune evasion but also directly inform novel therapeutic strategies. These include the identification of new immune checkpoints, the development of T cell receptor/neoantigen-targeted therapies, and approaches to reprogram or target suppressive myeloid cells. Furthermore, the construction of pre- and post-treatment single-cell atlases holds promise for predicting efficacy and overcoming resistance. This article also discusses current challenges and future directions in the field. In summary, scRNA-seq is propelling leukemia immunology toward deeper mechanistic understanding and laying the critical groundwork for the next generation of precision immunotherapies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: